JP2019517512A - 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 - Google Patents

結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 Download PDF

Info

Publication number
JP2019517512A
JP2019517512A JP2018563110A JP2018563110A JP2019517512A JP 2019517512 A JP2019517512 A JP 2019517512A JP 2018563110 A JP2018563110 A JP 2018563110A JP 2018563110 A JP2018563110 A JP 2018563110A JP 2019517512 A JP2019517512 A JP 2019517512A
Authority
JP
Japan
Prior art keywords
antibody
ctla
months
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517512A5 (enExample
Inventor
マイケル・アクセルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59078186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019517512(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019517512A publication Critical patent/JP2019517512A/ja
Publication of JP2019517512A5 publication Critical patent/JP2019517512A5/ja
Priority to JP2022155878A priority Critical patent/JP7721494B2/ja
Priority to JP2025093572A priority patent/JP2025143276A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018563110A 2016-06-03 2017-06-02 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 Pending JP2019517512A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022155878A JP7721494B2 (ja) 2016-06-03 2022-09-29 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
JP2025093572A JP2025143276A (ja) 2016-06-03 2025-06-04 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345662P 2016-06-03 2016-06-03
US62/345,662 2016-06-03
PCT/US2017/035822 WO2017210637A1 (en) 2016-06-03 2017-06-02 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022155878A Division JP7721494B2 (ja) 2016-06-03 2022-09-29 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用

Publications (2)

Publication Number Publication Date
JP2019517512A true JP2019517512A (ja) 2019-06-24
JP2019517512A5 JP2019517512A5 (enExample) 2020-07-16

Family

ID=59078186

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563110A Pending JP2019517512A (ja) 2016-06-03 2017-06-02 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
JP2022155878A Active JP7721494B2 (ja) 2016-06-03 2022-09-29 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
JP2025093572A Pending JP2025143276A (ja) 2016-06-03 2025-06-04 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022155878A Active JP7721494B2 (ja) 2016-06-03 2022-09-29 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
JP2025093572A Pending JP2025143276A (ja) 2016-06-03 2025-06-04 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用

Country Status (7)

Country Link
US (3) US11332529B2 (enExample)
EP (2) EP3464373B1 (enExample)
JP (3) JP2019517512A (enExample)
KR (3) KR102702675B1 (enExample)
CN (1) CN109476754A (enExample)
ES (1) ES2897964T3 (enExample)
WO (1) WO2017210637A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545504A (ja) * 2019-08-22 2022-10-27 アマゼンティス エスアー ウロリチンと免疫療法治療との組み合わせ

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
SG10201912035YA (en) * 2015-04-17 2020-02-27 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
AU2016294440B2 (en) 2015-07-13 2022-10-13 Cytomx Therapeutics, Inc Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
PL3334763T3 (pl) 2015-08-11 2024-12-02 WuXi Biologics Ireland Limited Nowe przeciwciała anty-pd-1
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
CN111770936A (zh) * 2018-01-12 2020-10-13 百时美施贵宝公司 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
BR112020015915A8 (pt) * 2018-02-13 2023-01-31 Merck Sharp & Dohme Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
WO2020033283A1 (en) * 2018-08-09 2020-02-13 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc
AU2019337547A1 (en) * 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022527177A (ja) * 2019-03-28 2022-05-31 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置する方法
CN110656179A (zh) * 2019-10-29 2020-01-07 至本医疗科技（上海）有限公司 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质
CN115569193B (zh) * 2021-10-09 2024-04-02 施慧达药业集团(吉林)有限公司 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法
EP4612182A1 (en) * 2022-10-31 2025-09-10 Agenus Inc. Methods of treating colorectal cancer using an anti-ctla4 antibody
TWI898418B (zh) * 2023-02-09 2025-09-21 安邦生技股份有限公司 用以治療大腸癌的藥學套組及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021743A1 (ja) * 2003-08-29 2005-03-10 Tanaka, Noriaki 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法
JP2005518798A (ja) * 2002-02-28 2005-06-30 アンスティテュ　ナシオナル　ド　ラ　サント　エ　ド　ラ　ルシュルシェ　メディカル（アンセルム） マイクロサテライト不安定性の検出のためのモノヌクレオチド反復マイクロサテライトマーカー
JP2014520515A (ja) * 2011-07-01 2014-08-25 ヘルシンキ・イリオピスト Ｄｎａミスマッチ修復機能を判別する方法
WO2016077553A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DK1212422T3 (da) 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5798919B2 (ja) 2008-08-25 2015-10-21 アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． Ｐｄ−１アンタゴニストの組成物および使用方法
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015210886A1 (en) * 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN106714836A (zh) 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
WO2018183408A1 (en) * 2017-03-31 2018-10-04 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518798A (ja) * 2002-02-28 2005-06-30 アンスティテュ　ナシオナル　ド　ラ　サント　エ　ド　ラ　ルシュルシェ　メディカル（アンセルム） マイクロサテライト不安定性の検出のためのモノヌクレオチド反復マイクロサテライトマーカー
WO2005021743A1 (ja) * 2003-08-29 2005-03-10 Tanaka, Noriaki 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法
JP2014520515A (ja) * 2011-07-01 2014-08-25 ヘルシンキ・イリオピスト Ｄｎａミスマッチ修復機能を判別する方法
WO2016077553A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ARCHIVE, NCT02060188 [ONLINE], 2016-05-25, [検索日2021-06-23], JPN6021025773, ISSN: 0004786176 *
DUNG T LE: "PD-1 BLOCKADE IN TUMORS WITH MISMATCH-REPAIR DEFICIENCY", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:372, NR:26, JPN5019004883, 30 May 2015 (2015-05-30), pages 2509 - 2520, ISSN: 0004786175 *
DURAISWAMY J: "DUAL BLOCKADE OF PD-1 AND CTLA-4 COMBINED WITH TUMOR VACCINE EFFECTIVELY RESTORES T-CELL 以下備考", CANCER RESEARCH, vol. VOL:73, NR:12, JPN5019004889, 15 June 2013 (2013-06-15), pages 3591 - 3603, ISSN: 0004545890 *
GUIDO KROEMER: "COLORECTAL CANCER: THE FIRST NEOPLASIA FOUND TO BE UNDER IMMUNOSURVEILLANCE AND THE LAST 以下備考", ONCOIMMUNOLOGY, vol. VOL:4, NR:7, JPN5019004886, 5 June 2015 (2015-06-05), pages 1058597 - 1, ISSN: 0004545888 *
LLOSA N J: "THE VIGOROUS IMMUNE MICROENVIRONMENT OF MICROSATELLITE INSTABLE COLON CANCER IS BALANCED 以下備考", CANCER DISCOVERY, vol. VOL:5, NR:1, JPN5019004887, 2015, US, pages 43 - 51, ISSN: 0004786177 *
MICHAEL A POSTOW: "MANAGING IMMUNE CHECKPOINT-BLOCKING ANTIBODY SIDE EFFECTS", AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK, vol. 35, JPN5019004888, June 2015 (2015-06-01), pages 76 - 83, ISSN: 0004545889 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545504A (ja) * 2019-08-22 2022-10-27 アマゼンティス エスアー ウロリチンと免疫療法治療との組み合わせ

Also Published As

Publication number Publication date
JP2023002567A (ja) 2023-01-10
EP3464373A1 (en) 2019-04-10
EP3988570A1 (en) 2022-04-27
KR20230047498A (ko) 2023-04-07
KR20190015406A (ko) 2019-02-13
US20220356254A1 (en) 2022-11-10
JP7721494B2 (ja) 2025-08-12
CN109476754A (zh) 2019-03-15
KR102702675B1 (ko) 2024-09-05
ES2897964T3 (es) 2022-03-03
US20250026831A1 (en) 2025-01-23
WO2017210637A1 (en) 2017-12-07
JP2025143276A (ja) 2025-10-01
EP3464373B1 (en) 2021-10-27
US20190153100A1 (en) 2019-05-23
US11332529B2 (en) 2022-05-17
KR20240134249A (ko) 2024-09-06
KR102515509B1 (ko) 2023-03-28

Similar Documents

Publication Publication Date Title
JP7721494B2 (ja) 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
AU2017274444B2 (en) Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in lymphoma treatment
CN106573977B (zh) 针对ceacam1的人源化抗体
JP2019503361A (ja) がんを治療するための抗ｐｄ−１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR20230144099A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
KR20220127940A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
JP2017520520A (ja) 非小細胞肺がんを治療するための抗ｂ７−ｈ１および抗ｃｔｌａ−４抗体
CN108699154A (zh) 对btla具有特异性的抗体及其用途
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2019517504A (ja) 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ−１遮断
JP2022547550A (ja) Ｐｄ－１軸阻害剤及び抗ペリオスチン抗体の使用により癌を処置する方法。
CN117980336A (zh) 抗tnfr2抗体及其用途
CN117603360A (zh) 用于治疗癌症的多特异性抗体
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
JP2024515879A (ja) 抗ｓｉｇｌｅｃ組成物及びその使用
EA050488B1 (ru) Композиции и способы для лечения рака легкого на поздней стадии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531